Abstract
Background and Aim: Hepatocellular carcinoma (HCC) is a type of liver cancer that accounts for 80% of primary liver malignancies. According to the WHO, 905677 new cases are discovered each year, with an 803180 mortality rate in 2020. Despite the multiple therapeutic options available, HCC treatment remains challenging due to its multifaceted pathophysiology and complexity caused by molecular and immunological heterogeneity. Overexpression of Apoptosis Antagonizing Transcription Factor (AATF) has been associated with HCC pathogenesis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
